Panacea Biotec Limited (PANACEABIO) AI Stock Analysis

• Market Cap: ₹26.48B
• Dividend Yield: N/A
• Average Volume (3M): 12.44K
• Price to Earnings (P/E): 230.6
• Beta (1Y): 1.73
• Revenue Growth: 9.78%
• EPS Growth: 50.78%
• Country: IN
• Employees: 1,936
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.27
• Shares Outstanding: 61,250,744
• 10 Day Avg. Volume: 14,140
• 30 Day Avg. Volume: 12,438
• PEG Ratio: -0.53
• Price to Book (P/B): 3.31
• Price to Sales (P/S): 4.94
• P/FCF Ratio: -35.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ₹361.00 ▼(-1.42% Downside)

Panacea Biotec faces significant financial and technical challenges. The company's negative profitability and cash flow issues are compounded by bearish technical indicators. The valuation is unattractive due to a negative P/E ratio and lack of dividends. These factors contribute to a low overall stock score.

Positive Factors

Strong Equity Position

A low debt-to-equity ratio suggests effective leverage management, providing financial stability and flexibility for future investments.

Gross Profit Margin

A high gross profit margin reflects efficient cost management, which can support profitability even amid revenue challenges.

Market Reach

Diverse market presence reduces dependency on a single region, enhancing resilience against localized economic downturns.

Negative Factors

Declining Revenue

Declining revenue indicates potential loss of market share or demand, which could impact long-term growth and profitability.

Negative Cash Flow

Negative cash flow from operations suggests liquidity issues, limiting the company's ability to reinvest and grow sustainably.

Negative Profitability

Consistent net losses and negative EBIT highlight operational inefficiencies, posing risks to financial health and investor confidence.

Panacea Biotec Limited Business Overview & Revenue Model

Company Description

Panacea Biotec Limited (PANACEABIO) is a biopharmaceutical company based in India, primarily engaged in the development, manufacture, and marketing of vaccines and biopharmaceuticals. The company operates in the sectors of vaccines, biotechnology, and pharmaceuticals, focusing on areas such as infectious diseases, oncology, and other health conditions. Its core products include a range of vaccines, therapeutic proteins, and biosimilars, catering to both domestic and international markets.

How the Company Makes Money

Panacea Biotec generates revenue through multiple streams, primarily from the sale of vaccines and biopharmaceutical products. The company markets its products to government health programs, hospitals, and private healthcare providers, both in India and globally. Additionally, Panacea Biotec engages in contract manufacturing for other pharmaceutical companies, providing an additional revenue source. Key partnerships with global health organizations and participation in government vaccination programs further enhance its revenue potential. The company also invests in research and development to innovate and expand its product offerings, which can lead to increased sales and market share.

Panacea Biotec Limited Financial Statement Overview

Summary

Panacea Biotec faces significant financial challenges, with declining revenue, negative profitability, and liquidity issues. Despite a strong equity position, the company struggles with cash flow generation and operational difficulties.

Income Statement

Panacea Biotec's income statement shows mixed performance with declining revenue and profitability. The gross profit margin for 2025 is approximately 64.31%, indicating decent cost management. However, the company has been experiencing negative EBIT and net income, reflecting operational challenges. The net profit margin is negative due to consistent net losses, and revenue growth has stagnated, showing no growth from 2024 to 2025.

Balance Sheet

The balance sheet indicates a strong equity position with a debt-to-equity ratio of 0.03 in 2025, showing effective leverage management. However, the company has faced declining total assets and stockholders' equity over the years. The equity ratio stands at 64.73% in 2025, suggesting a stable financial structure, but the decline in assets could be a concern for future growth.

Cash Flow

Panacea Biotec's cash flow statement reveals liquidity challenges, with negative operating cash flow and free cash flow in 2025. The company is struggling to generate cash from operations, reflected in the negative operating cash flow to net income ratio. The free cash flow to net income ratio is also negative, indicating a need for improvement in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.10B	5.59B	5.52B	4.57B	6.59B	6.18B
Gross Profit	3.75B	3.60B	446.53M	1.78B	3.42B	4.13B
EBITDA	540.00M	307.40M	415.37M	563.65M	16.74B	865.18M
Net Income	114.80M	-83.70M	-11.73M	-332.37M	10.78B	-1.48B
Balance Sheet
Total Assets	0.00	12.90B	12.41B	12.71B	17.59B	11.78B
Cash, Cash Equivalents and Short-Term Investments	1.10B	1.79B	1.56B	2.13B	5.52B	954.44M
Total Debt	0.00	222.10M	209.90M	202.19M	341.55M	8.20B
Total Liabilities	-8.31B	4.59B	4.02B	4.31B	8.85B	14.09B
Stockholders Equity	8.31B	8.35B	8.42B	8.44B	8.77B	-2.29B
Cash Flow
Free Cash Flow	0.00	-776.80M	-778.18M	-4.63B	-1.21B	850.01M
Operating Cash Flow	0.00	-273.70M	-1.00M	-4.22B	-1.08B	1.07B
Investing Cash Flow	0.00	649.80M	102.27M	4.30B	12.83B	-476.79M
Financing Cash Flow	0.00	-26.60M	-28.08M	-183.73M	-11.76B	-471.10M

Panacea Biotec Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 366.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Negative. The current price of 366.2 is below the 20-day moving average (MA) of 389.07, below the 50-day MA of 414.18, and below the 200-day MA of 429.84, indicating a bearish trend. The MACD of -17.40 indicates Positive momentum. The RSI at 38.52 is Neutral, neither overbought nor oversold. The STOCH value of 52.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PANACEABIO.

Panacea Biotec Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	74 Outperform	₹668.50B	19.71	―	0.33%	7.33%	-3.79%
IPCALAB	74 Outperform	₹368.60B	44.33	―	0.28%	9.66%	25.79%
ALKEM	72 Outperform	₹677.34B	29.65	―	0.79%	9.32%	11.25%
GLAXO	63 Neutral	₹450.87B	47.45	―	2.10%	4.17%	41.51%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.26%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	41 Neutral	₹26.48B	230.65	―	―	9.78%	50.78%

Panacea Biotec Limited Corporate Events

Panacea Biotec Announces 41st AGM Details and Compliance Measures

Panacea Biotec Limited announced the publication of a newspaper notice regarding its 41st Annual General Meeting, including details about the cut-off date and remote e-voting. This announcement is part of the company’s compliance with SEBI regulations, ensuring transparency and shareholder engagement in its governance processes.